Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Data from SB-300's Proof of Concept Trial for Treatment of Gastrointestinal Ulcers in Horses

Source Link:: http://phx.corporate-ir.net/phoenix.zhtml?c=253723&p=irol-newsArticle&ID=2122655

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

JAGX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment "Until recently, treatment recommendations for equine ulcers have not differentiated between squamous and glandular disease. However, a series of recent third-party studies indicate considerably lower healing rates for glandular ulcers with standard of care (e.g. omeprazole).3 Subclinically, these lesions can compromise athletic performance,” explained Lisa Conte, Jaguar’s president and CEO. “We are aiming to develop an FDA-approved first-in-class complete ulcer and gut treatment.

http://phx.corporate...

Additional Relevant Details According to a third-party 2005 study, as many as 55% of performance horses have colonic or gastric ulcers and 97% of performance horses have either a gastric (87%) or a colonic (63%) ulcer.4 Data from the American Horse Council states that there are currently 9.2 million horses in the U.S., a population that includes 844,531 race horses, more than 2.7 million show horses, and more than 3.9 million recreational horses

http://phx.corporate...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Feb 16, 2016

Occurred Source:

http://phx.corporate-ir.net/phoenix.zhtml?c=253723&p=irol-newsArticle&ID=2139505

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Animal Health, Sb-300, Gastrointestinal Ulcers In Horses